| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/19/2006 | US20060235000 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 10/19/2006 | US20060234999 Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration |
| 10/19/2006 | US20060234998 Compositions and methods for treating CNS disorders |
| 10/19/2006 | US20060234997 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
| 10/19/2006 | US20060234996 Novel crystalline form of ezetimibe and processes for the preparation thereof |
| 10/19/2006 | US20060234995 Compositions containing piperacillin and tazobactam useful for injection |
| 10/19/2006 | US20060234994 Method and device for concentrating and stabilizing conjugated estrogens from mare urine |
| 10/19/2006 | US20060234993 Use of androstane derivatives for enhancing physical performance |
| 10/19/2006 | US20060234992 DHEA composition and method |
| 10/19/2006 | US20060234991 Combinations for the treatment of immunoinflammatory disorders |
| 10/19/2006 | US20060234990 Compositions of boswellic acids derived from Boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 10/19/2006 | US20060234989 Formulations of quaternary ammonium neuromuscular blocking agents |
| 10/19/2006 | US20060234988 7-N-substituted phenyl tetracycline compounds |
| 10/19/2006 | US20060234987 Neuroprotective benzo 1 3 oxathiol 2 ones |
| 10/19/2006 | US20060234986 Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI |
| 10/19/2006 | US20060234985 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
| 10/19/2006 | US20060234984 Mitotic kinesin inhibitors |
| 10/19/2006 | US20060234983 Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| 10/19/2006 | US20060234982 Compositions and methods for combination antiviral therapy |
| 10/19/2006 | US20060234981 Topically treating ungal and periungal infections of the nails, hoofs and claws of mammals by treating with 1-hydroxy-5-fluoro-1,3-dihydro-2,1-benzoxyborole; effectively penetrates the nail; onychomycosis; tinea unguium; fungicides; viricides; bactericides; parasiticides; yeast; microbiocides |
| 10/19/2006 | US20060234980 Antiinflammatory agent, agent for preventing/ameliorating allergic diseases and functional food |
| 10/19/2006 | US20060234979 Inclusion complex in a beta-cyclodextrin, preferably, sulfobutyl ether beta-cyclodextrin, in the form of an injectable material; reducing irritation normally caused by aripiprazole at an intramuscular injection site; for treating schizophrenia |
| 10/19/2006 | US20060234978 Bone disorders; antiinflammatory agents; antiarthritic agents; mixture of chondroitin sulfate, n-acetylglucosamine and hyaluronic acid |
| 10/19/2006 | US20060234977 Antiviral compostion comprising a sulphated glucose polymer and a bacteriostatic agent |
| 10/19/2006 | US20060234976 Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles |
| 10/19/2006 | US20060234975 Use of adenosine receptor agonists in therapy |
| 10/19/2006 | US20060234974 2,6-Dihalogeno-8-substituent-purine compound and process for producing the same |
| 10/19/2006 | US20060234968 Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 10/19/2006 | US20060234963 Hepatitis C therapies |
| 10/19/2006 | US20060234962 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 10/19/2006 | US20060234961 Novel anti bacterial compounds |
| 10/19/2006 | US20060234960 Methods and compositions for increasing the safety and efficacy of albumin-binding drugs |
| 10/19/2006 | US20060234959 Photodynamic therapy utilizing multiple duty cycle light modulation |
| 10/19/2006 | US20060234958 Process of increasing cellular production of biologically active compounds |
| 10/19/2006 | US20060234957 Adiponectin expression promoter |
| 10/19/2006 | US20060234956 Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof |
| 10/19/2006 | US20060234955 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| 10/19/2006 | US20060234954 Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
| 10/19/2006 | US20060234953 e.g.1-(2,3,4,6-tetra-O-benzyl- beta -D-glucopyranos-1 -yl)-3-(4-hydroxy-benzyl)-4-methyl-benzene; treatment of metabolic disorders |
| 10/19/2006 | US20060234952 Combination therapy for effecting weight loss and treating obesity |
| 10/19/2006 | US20060234951 Combination therapy for effecting weight loss and treating obesity |
| 10/19/2006 | US20060234950 Combination therapy for effecting weight loss and treating obesity |
| 10/19/2006 | US20060234949 Adduct of topiramate and tramadol hydrochloride and uses thereof |
| 10/19/2006 | US20060234948 Lignan-containing compositions |
| 10/19/2006 | US20060234947 A synthetic dipeptide as set forth in SEQ ID NO: 145 - tryptophan-2-aminoisobutyric acid (D-Trp-Aib); diagnosing and treating Alzheimer's disease, non-insulin dependent diabtes; antdiabetic agents, prion-related encephalopathies such as bovine spongiform encephalo pathy |
| 10/19/2006 | US20060234946 Use of telmisartan for the prevention and treatment of vascular headache |
| 10/19/2006 | US20060234940 Secondary binding site of dipeptidyl peptidase IV (DP IV) |
| 10/19/2006 | US20060234939 Calcium channel modulator; delayed or sustained release |
| 10/19/2006 | US20060234937 Modulation of angiogenesis |
| 10/19/2006 | US20060234936 Method for screening substances capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells |
| 10/19/2006 | US20060234931 Treatment of diseases with kinase inhibitors |
| 10/19/2006 | US20060234929 Rasgap derived peptide for selectively killing cancer cells |
| 10/19/2006 | US20060234927 Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| 10/19/2006 | US20060234925 Embryo implantation inhibitor |
| 10/19/2006 | US20060234924 A kit for screening a compound or its salt that promotes or inhibits the activity of the proteins; drug screening for hyperlipemia, arteriosclerosis, genital, digestive, respiratory diseases, renal, pancreatic, central nerve, respiratory, inflammatory, rheumatoid diseases and diabetic neurosis |
| 10/19/2006 | US20060234922 Remedy for corneal failure |
| 10/19/2006 | US20060234913 Orally administering insulin and delivery agent 4-[(4-chloro, 2-hydroxybenzoyl)amino]butanoic acid that facilitates the absorption of insulin from the gastrointestinal tract; diabetes mellitus; bioavailability comparable to injection; treating diabetes without the drawbacks of systemic hyperglycemia |
| 10/19/2006 | US20060234912 Methods for modulating neuronal responses |
| 10/19/2006 | US20060234910 Methods for the treatment of insulin resistance and disease states characterized by insulin resistance |
| 10/19/2006 | US20060234909 Compositions and methods for increasing drug efficiency |
| 10/19/2006 | US20060234904 Method for preparing polymorphism of irinotecan hydrochloride |
| 10/19/2006 | US20060234349 Fungal cell wall synthesis gene |
| 10/19/2006 | US20060234344 Protein kinases |
| 10/19/2006 | US20060234342 Human DNA topoisomerase I alpha |
| 10/19/2006 | US20060234283 reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity |
| 10/19/2006 | US20060234278 Sequences used to identify if a female mammal comprises a mutation in the alpha-fetoprotein sequence(S) or a partial or total deletion of the alpha-fetoprotein sequence(S) |
| 10/19/2006 | US20060234271 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 10/19/2006 | US20060234212 Hepatitis-B viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
| 10/19/2006 | US20060233902 Compositions and foods for improving lipid metabolism |
| 10/19/2006 | US20060233899 Treatment of Human Multiple Myeloma by Curcumin |
| 10/19/2006 | US20060233897 Agent for preventing, improving or treating hypertension |
| 10/19/2006 | US20060233896 Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, Cistanche tubulosa (Schenk.) Wight, process of making the same, and uses of the same |
| 10/19/2006 | US20060233894 Anti-Inflammatory Humate Compositions and Methods of Use Thereof |
| 10/19/2006 | US20060233893 Aqueous solutions for the reduction of fatty tissue |
| 10/19/2006 | US20060233892 Topiramate compositions for treatment of headache |
| 10/19/2006 | US20060233890 Method for treating a mammal by administration of a compound having the ability to release CO |
| 10/19/2006 | US20060233886 Antimicrobial composition and method for making same |
| 10/19/2006 | US20060233883 Intravenous nanoparticles for targeting drug delivery and sustained drug release |
| 10/19/2006 | US20060233880 Controlled release dosage forms |
| 10/19/2006 | US20060233879 Reduced contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, advantageous for delivering an ulcerative drug |
| 10/19/2006 | US20060233878 Extended release formulation of beta-lactam antibiotics |
| 10/19/2006 | US20060233877 Betaine compositions |
| 10/19/2006 | US20060233876 Compositions and methods for reducing cardiovascular morbidity and/or mortality |
| 10/19/2006 | US20060233875 Taste masked sumatriptan tablets and processes for their preparation |
| 10/19/2006 | US20060233872 Pharmaceutical product which is used to reduced or stop moderate or severe snoring |
| 10/19/2006 | US20060233870 Compositions and methods for drug delivery |
| 10/19/2006 | US20060233869 Biocompatible, oxidized cellulose particles of specific size; and porous water soluble or water swellable polysaccharide binder; controlling post-surgical bleeding; medical equipment |
| 10/19/2006 | US20060233863 Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
| 10/19/2006 | US20060233862 Process for the preparation of a fat composition containing sterol esters a product obtained by said process and the use thereof |
| 10/19/2006 | US20060233861 Modulation of atp production or content in the hypothalamus |
| 10/19/2006 | US20060233860 Associated with diabetes; implanting an alpha-2 adrenergic receptor agonist, such as brimonidine tartrate, associated with a biodegradable polymer matrix; hypotensive agents, antiischemic agents; vision defects |
| 10/19/2006 | US20060233859 Methods for treating retinopathy with extended therapeutic effect |
| 10/19/2006 | US20060233853 Bone Growth Compositions and Methods |
| 10/19/2006 | US20060233845 Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics |
| 10/19/2006 | US20060233843 Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| 10/19/2006 | US20060233842 Microemulsion composition for oral administration of biphenyldimethyldicarboxylate |
| 10/19/2006 | US20060233841 Implantable gel compositions and method of manufacture |
| 10/19/2006 | US20060233835 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| 10/19/2006 | US20060233828 fatty acid synthase inhibitors |
| 10/19/2006 | US20060233815 Agents for protection from neointimal formation in grafts comprising an nfkappab decoy |